2016 年第 7 期 第 14 卷

子宫内膜癌患者的血清has-miR-141的表达及其临床意义

作者：

单位：

关键词：子宫内膜癌has-miR-141血清标志物

• 摘要：
• 【摘要】目的 探讨has-miR-141(Homo sapiens miR-141,miR-141)在子宫内膜癌患者血清中的表达及其临床意义。方法 收集2011年5月至2012年12月中国医学科学院肿瘤医院妇瘤科收治的55例子宫内膜癌患者术前24小时内的血清标本，以同期收治的12例子宫肌瘤患者术前24小时内的血清和5例健康志愿者的血清作为对照，应用实时荧光定量PCR技术检测子宫内膜癌患者和对照组血清中has-miR-141的表达水平，并分析has-miR-141表达水平与55例子宫内膜癌患者的临床病理危险因素的关系。结果 子宫内膜癌患者的血清has-miR-141的表达水平(2.6295±2.038)显著高于对照组（1.561±0.695）(P<0.05)。其中，子宫内膜样腺癌与非子宫内膜样腺癌患者血清has-miR-141的表达水平分别为（2.182±0.239）和（5.261±0.836），两者比较，差异具有统计学意义（P<0.01）；有盆腔淋巴结转移患者的血清has-miR-141的表达水平（4.846±0.11）显著高于无盆腔淋巴结转移者（1.363±0.090）（P<0.001）；III-IV期患者血清has-miR-141的表达水平（3.863±0.5308）显著高于I-II期的表达水平（2.030±0.2760）（t检验，P<0.05），但高、中、低分化子宫内膜癌患者的血清has-miR-141的表达水平（2.544±0.4728、2.614±0.4766、2.775±0.5114），差异并无统计学意义（P>0.05）。结论 子宫内膜癌患者血清中has-miR-141呈高表达水平，且它与淋巴结转移、病理类型及病理分期相关。has-miR-141有可能成为一种诊断子宫内膜癌的新型标志物，同时有可能作为进展期子宫内膜癌的诊断依据，从而为子宫内膜癌的诊段及治疗提供有效帮助。
• Objective In this study, we investigated the expression of the has-miR-141 in serum of endometrial cancer and clinical significance. Methods Collected 55 cases blood specimens within 24 hours before surgery operation from May. 2011 to Dec. 2012, and collected 12 cases from the patients of uterine myoma and 5 cases from the health of volunteers in comparison. Real-time quantity PCR was used to detect the expression of has-miR-141 in those specimens and analyzed clinical pathological risk factors with the expression of has-miR-141 in 55 cases of endometrial cancer. Results The expression of has-miR-141was (2.6295±2.038) in endometrial cancer, which was significant higher than that in control group(1.561±0.695)(P＜0.05). The expressions of has-miR-141 were （2.182±0.239）and （5.261±0.836）between endometrioid and non-endometrioid adenocarcinoma, and there were significant difference(P＜0.05). The expression were( 2.544±0.4728),(2.614±0.4766),(2.775±0.5114) in well, moderately and poorly differentiated endometrial cancer, respectively, while there were not significant difference (P>0.05). The expression of has-miR-141 were (4.846±0.4114) and (1.363±0.0903) times between lymph node metastasis and without lymph node metastasis in endometrial cancer , in which there were significant difference (P＜0.001). The expressions were (2.030±0.2760) and (3.863±0.5308) times in stage I-II and III-IV endometrial cancer, respectively, in which there were significant difference(P＜0.05). Conclusion. The has-miR-141 is high expression in serum of endometrial cancer, and it is closely related to lymph node metastasis, pathological types and staging. It may be a kind of new diagnosis marker in endometrial cancer, furthermore it may be used as the basis for the diagnosis of advanced endometrial cancer. Accordingly, it is useful in early diagnosis and treatment of endometrial cancer.